## **Optimizing Long-Term Outcomes** with Kidney Anti-rejection Therapies



This activity is jointly sponsored by



Impact Education, LLC

This activity is supported by an educational grant from





#### Acute and Chronic Rejection

Dr. Stuart M. Flechner Professor of Surgery, Glickman Urological and Kidney Institute Transplant Center Cleveland Clinic Lerner College of Medicine

# Absent Tolerance or Twins:

## All Transplants Reject......

What matters to recipients is how fast.....



## Prevalence of Allograft Failure/Rejection



Causes of Renal Graft Loss After First Year (130,000 transplants - 16,000 failures)



United Network for Organ Sharing Web site. http://www.unos.org. Accessed July 9, 2008.

#### **Chronic Allograft Nephropathy**

...the persistent inexorable decline in transplant renal function with time...



#### Antigen Dependent

Acute Rejection Re-Transplants HLA antibodies Non-HLA antibodies

#### Antigen Independent

Ischemia/Reperfusion Nephrons: age, gender, size **Nephrotoxic Drugs** Hypertension Hyperlipidemia CMV/other infections Hyperfiltration?

#### Clinical Manifestations of Acute Renal Allograft Rejection

#### • Local

- Pain and swelling over graft, redness
- Systemic
  - Fever and Chills
  - Lethargy
  - Decreased urine output
  - Edema and SOB
  - Hypertension
- Metabolic
  - Increased serum creatinine, BUN, potassium
  - Acidosis
  - Proteinuria

#### Kidney Transplant Outcomes One year Acute Rejection Rates (%)





## Causes of Failure/Rejection



#### Types of Renal Allograft Rejection



	<b>Hyperacute</b>	<u>Acute</u>	<u>Chronic</u>
Time after transplant	Minutes to Hours	Days to Years	Months to Years
Mediating Factors	Preformed anti-HLA or ABO antibodies: Class I or II	Cellular and humoral Immunity	Antigen dependent Antigen independent
Sequelae	Intravascular Coagulation	Tissue Destruction Tubular injury	Obliterative Graft Fibrosis
Prevention/ Therapy	ABO typing and lymphocyte crossmatching	Immunosuppression Induction therapy Maintenance therapy	Prevent AcR Control Secondary Risk Factors

## Normal Kidney





## Hyperacute Rejection





## Hyperacute Rejection: hemorrhagic necrosis





#### Hyperacute Rejection: platelet thrombi





#### HLA Antibodies Predict Kidney Graft Failure 2278 patients in 23 centers



## Acute Cellular Rejection





#### **Resolved Acute Rejection:** Post Steroids



#### T cell Depletion Alone Does Not Produce Tolerance

- Seven unsensitized LD recipients: No maintenance therapy
- C-1-H .3mg/kg plus iv MP 250-500mg- 3 doses pretransplant
- All seven with clinical rejection (<sup>↑</sup>SCr) day 14-28 (4/6 Banff I-II)
- CD3,4,or 8 Pos T cells absent in periphery during these AcR
- Diminished expression of T cell transcripts during AcR

Return of monocytes predate return of lymphocytes between weeks 2-3



#### The Process of Rejection – T Cell Trafficking



#### **BANFF Criteria:** Revised 2005



1. Normal

#### 2. Antibody Mediated Rejection-DSA identified

- 1. I. ATN-like; C4d+ minimal inflammation
- 2. II. Capillary margination and/or thrombosis, C4d+
- 3. III. Arterial C4d+
- 4. Chronic active antibody mediated rejection C4d+
- 3. Borderline changes-suspicious for acute T cell mediated rejection

#### 4. T cell Mediated Rejection

- Acute (i, t, v)
- Ia inflammation >25% parenchyma (i2 or i3); moderate tubulitis t2
- Ib inflammation >25% parenchyma (i2 or i3); severe tubulitis t3
- Ila cases with intimal arteritis (v1)
- IIb cases with severe intimal arteritis (v2)
- III transmural arteritis; fibrinoid changes; necrosis smooth muscle
- Chronic rejection (cv, cg)
- *arteriopathy-intimal fibrosis with mononuclear glomerulopathy-double contours GBM*

#### **BANFF Criteria:** Revised 2005



- 5. Interstitial Fibrosis and Tubular Atrophy (TAIF) without evidence of specific etiology
  - Grade I: mild TAIF < 25% of cortical area
  - Grade II: moderate TAIF 26-50% of cortical area
  - Grade III: TAIF >50% or cortical area
  - May include non-specific vascular and glomerular sclerosis, graded by TAIF
- 6. Other changes not rejection, acute or chronic
  - drug toxicity: CNI drugs
  - recurrent disease
  - viral infection: polyoma, cmv etc.
  - bacterial infection
  - severe hypertension



## Time Course of Failure/Rejection



#### The Fate of Renal Allografts -Immunosuppression



## Transplant Kidney: Day 0





### Transplant Kidney: Chronic Allograft Nephropathy



#### The Progression of Alloimmune Injury



Cheng et al AJT 2006; 6:2292

#### Chronic Immune Injury of Renal Allografts

#### **T-Cell Mediated (Cellular) Rejection**

<u>Targets</u> interstitium tubular epithelium arterial intima

#### <u>Results</u>

fibrosis atrophy, mesenchymal transition fibrous intimal thickening

#### **B-Cell Mediated (Humoral) Rejection**

<u>Targets</u> capillary endothelium (peri-tubular) glomeruli

#### **Results**

complement activation C4d and PMN margination double contours

#### Summary



- Acute and chronic rejection are the consequences of different HLA antigens on the donor and recipient.
  - the incidence of acute rejection episodes has diminished.
  - the incidence of chronic rejection may be increasing.
- The changes that occur in kidney grafts over time are due to both antigen dependent and antigen independent mechanisms.
- Histologic assessment of kidney grafts is the most accurate way to diagnose acute and/or chronic rejection, and to rule out other causes of renal dysfunction.
- Most rejection episodes are due to both cellular and humoral immune activation; detection of donor specific antibody before or after the transplant correlate with diminished graft outcome.